A high rate of aerobic glycolysis is a hallmark of malignant transformation. Accumulating evidence suggests that diverse regulatory mechanisms mediate this cancer-associated metabolic change seen in a wide spectrum of cancer. The echinoderm microtubuleassociated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion protein is found in approximately 3-7% of non-small cell lung carcinomas (NSCLC). Molecular evidence and therapeutic effectiveness of FDA-approved ALK inhibitors indicated that EML4-ALK is a driving factor of lung tumorigenesis. A recent clinical study showed that NSCLC harboring EML4-ALK rearrangements displayed higher glucose metabolism compared with EML4-ALK-negative NSCLC. In the current work, we presented evidence that EML4-ALK is coupled to overexpression of hexokinase II (HK2), one of the rate-limiting enzymes of the glycolytic pathway. The link from EML4-ALK to HK2 upregulation is essential for a high rate of glycolysis and proliferation of EML4-ALK-rearranged NSCLC cells. We identified hypoxia-inducible factor 1α (HIF1α) as a key transcription factor to drive HK2 gene expression in normoxia in these cells. EML4-ALK induced hypoxia-independent but glucose-dependent accumulation of HIF1α protein via both transcriptional activation of HIF1α mRNA and the phosphatidylinositol 3 kinase-AKT pathway to enhance HIF1α protein synthesis. The EML4-ALK-mediated upregulation of HIF1α, HK2 and glycolytic metabolism was also highly active in vivo as demonstrated by fluorodeoxyglucose-positron emission tomography imaging of xenografts grown from EML4-ALK-positive NSCLC cells. Our data reveal a novel EML4-ALK-HIF1α-HK2 cascade to enhance glucose metabolism in EML4-ALK-positive NSCLC.
INTRODUCTION
Cancer cells are metabolically transformed to respond to environmental changes. The most prominent aspect of metabolic transformation is the glycolytic phenotype or the Warburg effect, whereby cancer cells sustain a high rate of aerobic glycolysis. 1 Active glycolysis not only provides quick ATP but also serves as a primary route for carbon source required for biosynthesis of complex macromolecules in actively proliferating cancer cells. 2 The metabolic switch from oxidative phosphorylation to hyperactive glycolysis is mediated by overexpression or hyperactivity of glucose transporters and/or key glycolytic enzymes as a result of activation of oncogene and/or inactivation of tumor suppressors. 3 The oncogenes Ras, AKT and c-Myc have been reported to promote expression of various glycolytic enzymes. 4, 5 In contrast, loss of the p53 tumor suppressor inhibits the mitochondrial respiratory chain by suppression of SCO2 (the synthesis of cytochrome c oxidase protein) and promotes glycolysis via TIGAR, a p53-inducible regulator of glycolysis and apoptosis. 6 The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion oncogene arises from an inversion on the short arm of chromosome 2 that joins the N-terminus of EML4 to the intracellular catalytic domain of ALK in patients with non-small cell lung cancer (NSCLC). First described in 2007 by two independent groups, 7, 8 the fusion protein was now found in 3-7% of NSCLC patients. 8, 9 The fusion oncogene is transforming both in vitro and in vivo. 8 Molecular evidence and therapeutic effectiveness of FDA-approved ALK inhibitors demonstrate that EML4-ALK is a driving factor of lung tumorigenesis. 10, 11 NSCLC harboring the EML4-ALK fusion oncogene is associated with specific clinical features, such as never or light smoking history and younger age. [12] [13] [14] In addition, EML4-ALK rearrangement does not overlap with mutations of epidermal growth factor receptor or K-Ras. 12 Therefore, the EML4-ALK fusion oncogene defines a distinct clinicopathologic subset of NSCLC.
There have been few studies of metabolic characteristics of EML4-ALK-positive NSCLC although this molecularly defined subtype of lung cancer represents an ideal model to investigate the role of oncogenes in metabolic transformation. Through analysis of fluorodeoxyglucose-positron emission tomography (FDG-PET) images of NSCLC patients, Choi et al. 15 recently reported that EML4-ALK-rearranged NSCLC exhibited higher glucose metabolism than NSCLC patients negative for EML4-ALK, implying a potential role of EML4-ALK in reprogramming glucose metabolism. In the present work, we showed that EML4-ALK is causally linked to hexokinase II (HK2) overexpression and the glycolytic phenotype of EML4-ALK-positive NSCLC. The ALK kinase activity induced hypoxia-independent accumulation of hypoxiainducible factor 1α (HIF1α) via both transcriptional and posttranscriptional mechanisms. Abundant HIF1α in turn acts as a primary transcription factor to stimulate HK2 expression, contributing to active glycolysis in EML4-ALK-rearranged NSCLC. Suppression of HK2 expression mimics the effects of EML4-ALK inactivation on glycolytic metabolism and proliferation of these cells. The EML4-ALK-mediated upregulation of HIF1α, HK2 and glucose catabolism was also fully reproducible in vivo as demonstrated by FDG-PET imaging of xenografts of EML4-ALK-positive lung cancer cells. These results revealed a novel EML4-ALK-HIF1α-HK2 pathway to drive glycolytic metabolism in EML4-ALK-rearranged NSCLC.
RESULTS

EML4-ALK activates aerobic glycolysis
A recent clinical study demonstrated that NSCLCs with EML4-ALK rearrangement have higher FDG uptake than those carrying epidermal growth factor receptor mutation or lacking known genetic aberrations, implying a potential role of EML4-ALK in glucose metabolic reprogramming. 15 NPM-ALK, another form of ALK arrangement in anaplastic large-cell lymphoma, has been recently shown to phosphorylate pyruvate kinase M2 (PKM2), leading to inhibition of the enzyme activity and prevention of oxidative phosphorylation. 16 Therefore, we examined whether EML4-ALK is linked to upregulation of glucose metabolism in ALK-rearranged NSCLC. To this end, we took advantage of two well-defined NSCLC cell lines H3122 and H2228 known to harbor variant 1 and variant 3 of EML4-ALK, respectively.
12 Variant 1 and variant 3 are generated by exons 13 and 6 of EML4 joined to exon 20 of ALK, respectively, 17 and account for 460% of all EML4-ALK rearrangements in NSCLC. 18 Lentivirally mediated short hairpin RNA (shRNA) targeting ALK efficiently knocked down EML4-ALK expression in both cell lines (Figure 1a) . Downregulation of EML4-ALK significantly decreased glycolysis and lactate production in these cells. Similar effects were observed when H2228 and H3122 cells were treated with ceritinib, a second-generation ALK inhibitor for the treatment of ALK-positive NSCLC 11, 19 ( Figure 1b ). It should be pointed out that the expression of wild type ALK was undetectable in these cell lines, consistent with the fact that ALK expression was extremely low in adult tissues. 20 Expression of EML4-ALK is associated with upregulation of HK2 The elevated glucose utilization in tumors has been attributed primarily to upregulation of either glucose transporters or ratelimiting glycolytic enzymes. 21 To elucidate the molecular mediator sustaining the glycolytic rate in EML4-ALK-positive cells, we examined the expression of glucose transporters and major glycolytic enzymes. Knockdown of EML4-ALK moderately increased expression of GLUT1 but did not affect that of GLUT3 (Figure 2a) , two major glucose transporters in lung cancer. 22 Among the multiple glycolytic enzymes HK1, HK2, PFK1, PKM2,  LDHA, PGAM1, Enolase-1 and GAPDH we examined, only ( Figure 2b) . Thus, the presence of the EML4-ALK fusion protein is concurrent with selective upregulation of HK2 in EML4-ALKpositive lung cancer cells. To confirm a causal role for EML4-ALK in upregulation of HK2, we used the pCDH-CMV-MCS-EF1-Puro lentivirus system to express EML4-ALK variant 1 in two EML4-ALK-negative cancer cell lines A549 and A431. Indeed, introduction of EML4-ALK markedly enhanced HK2 protein expression in both cell lines (Figure 2c ). HK2 mediates the metabolic effects of EML4-ALK To further understand the role of upregulated HK2 in EML4-ALKpositive NSCLC cells, we examined the effect of HK2 silencing on glycolysis in H2228 and H3122 cells. As shown in Figure 3 , shRNA knockdown of HK2 expression suppressed glycolytic flux and HK activity in these cells. The inhibitory effects were directly related to the knockdown efficiencies of HK2 shRNAs with HK2-sh4 causing more marked decrease in glycolysis and HK activity (Figures 3b  and c) . Similarly, HK2 silencing also attenuated proliferation of H2228 and H3122 cells (Figure 3d ), suggesting that EML4-ALK-mediated induction of HK2 is functionally important for sustaining active glycolysis and proliferation of EML4-ALK-positive NSCLC cells.
To confirm that the hyperactive glycolysis in EML4-ALK-positive NSCLC cells is truly because of ALK-driven HK2 overexpression, we first knocked down EML4-ALK to bring down cellular HK2 level and then introduced a flag-tagged HK2 under the control of the CMV promoter independent of ALK regulation. In these cells, exogenous HK2 reversed the inhibitory effects of ALK knockdown on glycolysis and HK activity (Figure 4) . However, ectopic expression of HK2 only partially rescued the growth rate of ALK knockdown cells (Figure 4d ), indicating that the ALK-HK2-glycolysis pathway is required but insufficient for ALK-driven cell proliferation. Other effectors downstream of ALK must act cooperatively to promote cell growth.
EML4-ALK drives HK2 expression through transcriptional activation We next explored the molecular mechanism underlying the EML4-ALK-dependent induction of HK2. Quantitative PCR (qPCR) was performed to measure the steady-state levels of HK2 mRNA in parental H2228 and H3122 cells (Supplementary Figure S1 ) and in EML4-ALK-depleted and the corresponding control cells. As shown in Figure 5a , shRNA knockdown of EML4-ALK resulted in marked decrease in HK2 mRNA, indicating that EML4-ALK stimulates HK2 expression via upregulation of HK2 transcripts. In further support of this, introduction of EML4-ALK into A549 cells led to a multifold increase in HK2 mRNA.
We took advantage of the highly responsive A549 cells to explore the transcriptional mechanism leading to HK2 overexpression. The HK2 gene promoter (from − 1476 to +73) was cloned into the pGL2-Basic-Luc reporter to construct pGL2-1476HK2-Luc. Co-transfection of pGL-1476HK2-Luc with pcDNA3.1/Zeo(+)-EML4-ALK, a variant 1 EML4-ALK expression vector, in A549 cells resulted in strong induction of luciferase activity from the HK2 promoter ( Figure 5b ). A series of nested 5′ deletions of the HK2 promoter (pGL2-273HK2-Luc and pGL2-138HK2-Luc) were constructed and tested. The major luciferase activity remained intact when HK2 promoter was shortened to − 138 bp ( Figure 5b ). The transactivation of the HK2 promoter by EML4-ALK depended entirely on ALK kinase activity. Two kinase dead mutants of EML4-ALK (I1250T and K1150A) 23, 24 failed to transactivate the HK2 promoter (Figure 5b ), although they were almost equally expressed in transfected cells (Figure 5c ).
HIF1α is a key transcription factor mediating HK2 upregulation in EML4-ALK-expressing cells The DNA sequences (−138 to +73) of the HK2 gene promoter responsive to ALK contain potential binding sites for multiple transcription factors, including those for NF-Y, NF-1, SP-1, CREB, AP-2, GCF and HIF1, as predicted from PROMO analysis. 25 Among these regulatory elements, the putative hypoxia response element (HRE) for HIF1 is of particular interest. A functional HRE is usually composed of a pair of contiguous sites, at least one of which contains the core sequence 5′-RCGTG-3′, 26, 27 which is exactly the case with the HRE located at − 60/ − 49 upstream of the HK2 transcription start site. This prompted us to test whether HIF1 was involved in activation of the HK2 gene. Interestingly, mutation of the HRE site located at − 60/ − 49 of the HK2 promoter inhibited EML4-ALK activation of the HK2 gene promoter as reflected by loss of 475% luciferase activity in A549 cells transfected with the HRE mutant reporter (Figure 6a and Supplementary Figure S2 ). The weak remaining activity could be due to the existence of other minor yet HIF1-independent factors downstream of EML4-ALK.
To gain direct evidence that HIF1α binds to the − 60/ − 49 HRE region of the native HK2 promoter to activate its transcription, we performed chromatin immunoprecipitation (ChIP) assay in H2228 and H3122 cells, and in EML4-ALK-transduced A549 cells. The qPCR analysis of HIF1α immunoprecipitates showed that EML4-ALK knockdown resulted in 28-and 9-fold decreases in the binding of HIF1α to the − 60/ − 49 HRE in H2228 and H3122 cells, respectively ( Figure 6b ). In EML4-ALK-transduced A549 cells, there was a 173-fold increase in HIF1α binding to the HRE region over the control cells lacking EML4-ALK (Figure 6b ). EML4-ALKdependent induction of HIF1α binding to the HK2 promoter was also readily detected by regular PCR analysis of HIF1α immunoprecipitates (Figure 6c ). Hence, EML4-ALK expression led to robust increases in HIF1α binding to the HK2 promoter at the − 60/ − 49 HRE. EML4-ALK induces hypoxia-independent but glucose-dependent accumulation of HIF1α Consistent with the luciferase reporter and ChIP assays, basal HIF1α protein, but not HIF2α, was readily detectable in both H2228 and H3122 cells (Figure 7a and Supplementary Figure S3) , in contrast to absent or low expression of HIF1α in most other cancer cell lines in normoxic conditions. The inactivation of EML4-ALK by shRNA silencing or ceritinib was accompanied by diminished HIF1α protein in these cells. Conversely, ectopic expression of EML4-ALK in A549 cells increased HIF1α protein (Figure 7a ), indicating that EML4-ALK is sufficient to enhance HIF1α protein abundance independently of hypoxia. To confirm that the abundantly present HIF1α is responsible for HK2 overexpression in H2228 and H3122 cells, we used HIF1α small interfering RNA (siRNA) to transiently knockdown its expression. This led to significant decreases in protein levels of not only HIF1α but also HK2 (Figure 7b) .
In addition to oxygen shortage, other environmental or nutritional factors including glucose availability have been shown to protect HIF1α protein through inhibition of lysosomal degradation of HIF1α, an oxygen and pVHL-independent arm of control of HIF1α protein. 28, 29 We therefore asked whether ALKdependent accumulation of HIF1α is influenced by glucose availability. When shifted from high to low concentrations of glucose (from 2 to 0.05 g/l), H2228 and H3122 cells exhibited much reduced HIF1α protein (Figure 7c ). The abundance of HIF1α was recovered by addition of glucose back to culture in an ALK activity-dependent manner (Figure 7d ). In further support of a crucial role for HIF1α in mediating HK2 transcription, HK2 protein was also similarly up and downregulated under these high and low glucose conditions (Figures 7c and d) .
If EML4-ALK is causally linked to elevated HIF1α protein, one may expect that other known HIF1α target genes such as GLUT1 and LDHA, in addition to HK2, should be similarly upregulated in EML4-ALK-expressing cells. As shown earlier, we did not detect significant changes in protein expression of GLUT1 and LDHA in EML4-ALK stable knockdown cells (Figure 2 ). However, when we examined mRNA of GLUT1 and LDHA, we found that depletion of EML4-ALK caused obvious decreases in GLUT1 and LDHA mRNA (Supplementary Figure S4) . Consistent with this, GLUT1 and LDHA mRNAs but not their proteins were elevated in EML4-ALK stably transduced A549 cells (Supplementary Figure S4) . Such discrepancy suggests that HIF1α-mediated transcriptional activation is not necessarily sufficient to enhance protein level expression of other HIF1α-targeted genes.
The phosphatidylinositol 3 kinase (PI3K)-AKT pathway is required for ALK upregulation of HIF1α protein synthesis Previous studies showed that the NPM-ALK fusion protein in T-cell lymphoma cell lines and EML4-ALK in NSCLC cells stimulated transcription of HIF1α mRNA through signal transducer and activator of transcription 3 (STAT3) 30 or through cooperation of STAT3 with CEBP/β. 31 In both cases, however, enhanced HIF1α protein was seen only in hypoxia, consistent with the concept that O 2 -dependent proteasomal degradation of HIF1α has a dominant role in the control of HIF1α homeostasis. 32 In our hands, HIF1α mRNA was moderately but significantly increased in EML4-ALKexpressing cells. HIF1α mRNA levels were up or downregulated in accordance with overexpression of EML4-ALK in A549 cells or inactivation of ALK by shRNA knockdown in H2228 and H3122 cells (Figure 8a) . Thus, our data confirmed that ALK-mediated accumulation of HIF1α protein involves transcriptional activation of HIF1α.
As the transcriptional regulation is usually insufficient to maintain HIF1α abundances under normoxia, we asked whether other post-transcriptional processes are implicated in upregulation of HIF1α protein. AKT has been reported to enhance HIF1α abundance in cells that overexpress oncogenic tyrosine kinases such as ErbB2 or activating mutant of AKT. 33, 34 The PI3K-AKT pathway is particularly relevant as EML4-ALK constitutively activates PI3K. 20, 35 Interestingly, pharmacological inhibition of PI3K, AKT and mammalian target of rapamycin (mTOR) with LY294002, MK2206 and rapamycin, respectively, markedly decreased levels of HIF1α protein in H2228 and H3122 cells (Figure 8b) . None of these inhibitors of the PI3K-AKT-mTOR pathway, however, negatively affected HIF1α mRNA (Figure 8b ). Only the ALK inhibitor ceritinib reduced both protein and mRNA expression of HIF1α. Consistent with an essential role of the PI3K-AKT-mTOR pathway in promotion of HIF1α protein synthesis, treatment with ceritinib, LY294002, MK2206 or rapamycin led to dephosphorylation of 4E-BP1 (Figure 8b and Supplementary Figure S5 ), a biochemical process associated with functional activation of the translational repressor. These results together indicate that the PI3K-AKT-mTOR pathway is important for EML4-ALK upregulation of HIF1α protein synthesis.
To obtain molecular evidence for involvement of AKT, we took advantage of siRNA that was designed to silence both AKT1 and AKT2 isoforms simultaneously. Knockdown of AKT1/2 in H2228 and H3122 cells brought down HIF1α protein level with no concomitant decrease in HIF1α mRNA (Figure 8c) . Instead, HIF1α mRNA was moderately increased in AKT1/2 knockdown cells. Similar to the inhibitors of ALK, PI3K, AKT and mTOR, AKT1/2 siRNA also triggered dephosphorylation of 4E-BP1. Consistent with HIF1α being a primary transcription activator of HK2, AKT1/2 siRNA also decreased HK2 expression in these cells. ChIP: regular PCR ChIP: qPCR Figure 6 . HIF1α is a key transcription factor upregulating HK2 expression in EML4-ALK-expressing lung cancer cells. (a) The HK2 luciferase reporter pGL2-138HK2-Luc or the HRE mutant form was co-transfected into A549 cells along with pCDNA3.1/Zeo(+) (vector) or pCDNA3.1/Zeo (+)-EML4-ALK. The transactivation of the HK2 promoter by co-transfected ALK was measured by luciferase assays. The luciferase activities were presented as fold changes relative to the value of the vector control cells (defined as onefold). ChIP assay was performed to assess the binding of HIF1α to the HK2 promoter in ALK knockdown and control cells of H2228 and H3122 and in A549 cells transduced to express EML4-ALK. The HK2 promoter DNA sequence co-precipitated with HIF1α was analyzed by qPCR using SYBR Green (b). (c) Fractions of immunoprecipitates and total cellular DNA were also analyzed with regular PCR amplification of the HK2 promoter using primers listed in Table 1 . detected by PET scanning. As our data suggest that the high rate of glycolysis in the EML4-ALK-positive subset of NSCLC is attributed to the kinase activity of EML4-ALK, we next examined whether inhibition of EML4-ALK is sufficient to limit glucose catabolism in xenografts of H3122 cells in immunodeficient SCID mice. H3122 cells were subcutaneously injected in SCID mice. Ten days after cell injection, the mice carrying palpable xenografts were randomly divided into experiment and control groups for treatment with ceritinib (25 mg/kg, daily) or vehicle for 5 days. The FDG-PET scanning was conducted before treatment, and then in the middle (2.5 days) and at the end (5 days) of the treatment. As shown in Figure 9a , ceritinib resulted in a remarkable decrease in values of the percent injected dose/g of tissue (%ID/g) in the xenografts. The difference between treatment and control groups was strikingly significant after treatment with cerinitib for only 2.5 days when tumors showed little reduction in volume (Figures 9a and b) . We also examined the effects of ceritinib on expression of HIF1α, HK2, p-AKT and p-4E-BP1 in the xenografts after 5 days of treatment when the animals were killed. As expected, expression HIF1α, HK2, p-AKT and p-4E-BP1 proteins was reduced in the xenografts from mice treated with ceritinib ( Figure 9c ). These results indicate that the EML4-ALK-HIF1α-HK2 axis to regulate glycolysis is fully operational in vivo. Inhibition of EML4-ALK was sufficient to disrupt the signaling from the ALK oncogene to glucose metabolism in mice. DISCUSSION EML4-ALK-rearranged lung cancer represents a molecularly defined subset of NSCLC, wherein ALK is clearly one of the oncogenic drivers. 36 A recent clinical study found that this subset of lung cancer exhibited higher glucose metabolism and metastatic potential than EML4-ALK-negative NSCLC. 15 We examined the hypothesis that oncogenic ALK is causally linked to the hyperactive glycolysis in EML4-ALK-positive NSCLC. Our results identified a novel regulatory pathway EML4-ALK-HIF1α-HK2 that upregulates glycolysis specifically in EML4-ALK-positive NSCLC cells. Brief exposure to an ALK inhibitor is sufficient to decrease glycolytic metabolism in EML4-ALK-positive xenografts, which could be monitored by FDG-PET scans in live animals.
Hexokinases catalyze ATP-dependent conversion of glucose to glucose-6-phosphate, the irreversible first rate-limiting step of glucose metabolism.
37 Glucose-6-phosphate then serves as a cosubstrate for both glycolysis and the pentose phosphate pathway. Although a high rate of glycolysis is essential for providing quick ATP and carbon source for biosynthesis, pentose phosphate pathway is a critical route for producing nucleotides required by actively replicating cancer cells. 38 Among the four isoforms of hexokinase, HK2 is aberrantly overexpressed in cancer. 39, 40 The higher affinity for substrate, lower sensitivity to negative feedback from product and greater catalytic power of HK2 compared with other hexokinase isoforms are likely the metabolic reasons for the propensity of tumors to selectively overexpress HK2. 41 The N-terminal hydrophobic domain allows HK2 to interact with voltage-dependent anion channel at the mitochondria and to gain preferential access to mitochondrially generated ATP to facilitate HK reaction. 41 Substantial studies have shown the essentiality of HK2 in growth, survival and tumorigenesis of different types of cancer including glioblastoma multiforme, medulloblastoma, K-Ras-driven lung cancer, ErbB2-driven breast cancer and PTEN-/p53-deficiency-induced prostate cancer. [42] [43] [44] [45] It is noteworthy that HK2 is expressed only in a limited number of adult tissues. 37 There are no adverse physiological consequences with systemic HK2 deletion in a mouse model. 43 Therefore, HK2-selective inhibitors could be promising anticancer agents. 46 Cancer cells upregulate HK2 expression and activity via diverse molecular mechanisms including gene amplification, transcriptional activation by p53 deficiency, Ras, AKT, c-Myc or HIF, downregulation of miR-143, and promoter demethylation. [47] [48] [49] [50] [51] [52] [53] HIF1α is a crucial transcription factor to drive expression of HK2 and other glycolytic enzymes in the adaptive response to hypoxia. 54 However, hypoxia is not the causal determinant of the glycolytic phenotype that occurs in both hypoxic and oxygenated regions of a tumor. Tumor cells in vitro also rely on glycolysis even when cultured in normoxic conditions. Involvement of HIF1α in hypoxia-independent overexpression of HK2 has not been yet demonstrated. Our study suggests that oncogenic ALK mediates In all panels, qPCR results were normalized to 18S ribosomal RNA and presented as values relative to the corresponding control cells (defined as onefold).
transcriptional and translational upregulation of HIF1α to increase HIF1α protein synthesis. In the presence of appropriate glucose concentrations to prevent chaperone-mediated lysosomal degradation, HIF1α protein is sufficiently accumulated to activate the downstream HK2 gene expression to promote glucose metabolism in normoxia. Another interesting aspect of our observation is that the ALK-HIF1α signaling induced mRNA expression of other known HIF1α target genes such as GLUT1 and LDHA in addition to HK2. At the protein level, however, only HK2 was elevated.
The selectivity suggests that gene expression in response to HIF1α activation is more complicated than transcriptional impact.
Other post-transcriptional processes likely have critical roles in delivering functional outcomes of HIF1α activation in a genespecific manner. In addition to NSCLC, ALK rearrangements through chromosomal translocations are found in anaplastic large-cell lymphomas, large B-cell lymphoma, neuroblastoma, inflammatory myofibroblastic tumors, renal cell carcinoma and ovarian cancer. 20, 55 It is unlikely that the effect of ALK on HIF1α, HK2 and glycolysis is restricted to EML4-ALK-positive NSCLC. The currently available methods to diagnose EML4-ALK-positive NSCLC are fluorescence in situ hybridization, immunohistochemistry and reverse transcriptase-PCR analyses of tumor biopsies. 56 Priorities are given to more prevalent epidermal growth factor receptor mutation followed by that of Ras. 57 If they are negative, EML4-ALK will be considered. This is a lengthy process and a significant proportion of EML4-ALK-positive NSCLC are never identified or only diagnosed after the commencement of conventional chemotherapies. In this study, we showed that the FDA-approved ceritinib strongly reduced glycolytic rate in xenografts grown from EML4-ALK-positive NSCLC cells. A marked decrease was observed after treatment for only 2.5 days. The decrease occurred before a significant reduction in tumor volume. The causal link from ALK to glycolysis could be exploited to distinguish EML4-ALK-positive NSCLC from EML4-ALK-negative NSCLC with FDG-PET scans following 2-3 days administration of ceritinib. This could provide a quick and non-invasive approach to determining ALK status, which is critical for timely and effective treatment of ALK+ NSCLC with appropriate ALK-targeted inhibitors. The application of the current findings could be more useful in many parts of the world where routine examination of ALK status is not available to NSCLC patients.
MATERIALS AND METHODS
Cell culture and reagents
The cell lines H2228, A549 and A431 were originally obtained from ATCC (Manassas, VA, USA). H3122 was obtained from NCI (Bethesda, MD, USA). All the cell lines were authenticated in July 2015 by STR DNA fingerprinting at the Characterized Cell Line Core Facility of MD Anderson Cancer Center (Houston, TX, USA). H2228, H3122 and A549 were cultured in RPMI-1640 with 10% fetal bovine serum. A431 was cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. D- [5- 3 H(N)]-glucose was obtained from Perkin Elmer (Boston, MA, USA). Ceritinib, MK2206 and rapamycin were purchased from Selleckchem (Houston, TX, USA). LY294002 was from Cell Signaling (Danvers, MA, USA).
Plasmids and lentivirus
The shRNA target sequences for ALK 43 and HK2 (ref.58) (Table 1) were cloned into the shRNA lentiviral vector pGreenPuro (System Biosciences, Mountain View, CA, USA). EML4-ALK and HK2 with Flag-tag at the C-terminus were cloned into the lentiviral vectors pCDH-CMV-MCS-EF1-Puro and pCDH-CMV-MCS-EF1-neo (System Biosciences), respectively. Recombinant lentivirus was produced by co-transfection into 293TN cells with lentiviral vectors and packaging plasmids using lipofectamine 2000 (Life Technologies, Frederick, MD, USA). Culture supernatants were collected 48 h after transfection and used to infect target cells. The infected cells were selected with puromycin or G418 to establish stably transduced cells.
Small interfering RNA
The siGENOME siRNAs for the human HIF1α were obtained from Dharmacon (Lafayette, CO, USA). AKT1/2 siRNA were purchased from Cell Signaling. H2228 or H3122 were transfected with siRNAs using DharmaFECT 1 according to the manufacturer (Dharmacon). Twenty-four hours after transfection, cells were incubated with fresh complete medium for another 48 h before protein and mRNA analysis.
Cell growth
Cells were plated and cultured in 12-well plates. Cell numbers were determined after indicated treatments using a Z1 Coulter counter (Beckman Coulter, Sykesville, MD, USA).
Glycolysis
The glycolytic rate was measured by quantification of the conversion of 5-3 H-glucose to 3 H 2 O as we described previously. 58 The glycolytic rate was presented as μmol glucose/h per 10 6 cells.
Lactate production
Lactate levels in culture supernatants were measured with a colorimetric lactate quantification kit according to the manufacturer (Eton Bioscience, San Diego, CA, USA). The concentrations were normalized on cell numbers.
HK activity HK activity in cell homogenates was measured as we described recently. 58 The results were normalized on protein contents of samples. 
Western blot analysis
Lysates from cells or xenografts were prepared in RIPA buffer supplemented with protease/phosphatase inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). Proteins were analyzed by immunoblotting as previously described. 58 The antibodies for ALK, β-tubulin, phospho-ALK Y1604 , HK1, HK2, PFK1, GAPDH, PKM2, LDHA, PGAM1, Enolase-1, AKT, phospho-AKT S473 and phospho-4E-BP1 T37/46 were purchased from Cell Signaling. The antibodies for GLUT1 and GLUT3 were obtained from Abcam (Cambridge, MA, USA). The HIF1α antibody was from BD Biosciences (San Jose, CA, USA).
Luciferase assay
The human HK2 gene promoter sequences (−1476 to +73, − 273 to +73, or − 138 to +73) were cloned into pGL2-Basic-Luc as we described recently. 58 The HIF1α binding consensus within the − 138 to +73 fragment was converted into inactive sequences (Table 1) by QuikChange II site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA). For co-transfection along with luciferase vectors, EML4-ALK complementary DNA was subcloned into pcDNA3.1/Zeo(+). The two ALK kinase dead mutants pCDNA3.1/Zeo(+)-EML4-ALK I1250T and pCDNA3.1/Zeo(+)-EML4-ALK K1150A 23,24 were generated by site-directed mutagenesis (Table 1) . DNA sequences in all these plasmids were authenticated by automatic sequencing.
A549 cells were co-transfected with the luciferase reporter vectors along with EML4-ALK expression plasmids using TransIT-LT1 (Mirus Bio, Madison, WI, USA). Forty-eight hours after transfection, cell extracts were prepared and assayed with the luciferase assay kit from Promega (Madison, WI, USA).
ChIP assay
ChIP assay was performed as described previously. 59 Briefly, nuclear fractions were extracted and chromatin was sonicated to achieve an average length of 200-1000 bp after cells were cross-linked with formaldehyde. Ten percent of the starting material was used as input controls. DNA-protein complexes were immunoprecipitated with HIF1α antibody or control IgG. The immunoprecipitates and input samples were reversed at 65°C overnight and then digested with Proteinase K. DNA samples were purified with the QIAquick Spin Columns (Qiagen, Valencia, CA, USA) and quantified by qPCR with the QuantiNova SYBR Green PCR Kit (Qiagen) using primers in Table 1 .
